Side effects during chemotherapy predict tumour response in advanced colorectal cancer

British Journal of Cancer

Volumn 93, Issue 7, 2005, Pages 744-748

  Schuell, B ^a   Gruenberger, T ^a   Kornek, G V ^a   Dworan, N ^a   Depisch, D ^b   Lang, F ^c   Schneeweiss, B ^a   Scheithauer, W ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b General Hospital Wiener Neustadt   (Austria)

^c Krankenhaus Neunkirchen   (Austria)

Author keywords

Chemotherapy; Colorectal cancer; Side effects; Treatment efficacy

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE; IRINOTECAN; OXALIPLATIN; RALTITREXED;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DISEASE CONTROL; DISEASE SEVERITY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NAUSEA; PRIORITY JOURNAL; RELIABILITY; SENSORY NEUROPATHY; STATISTICAL ANALYSIS; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 27144508760     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602783     Document Type: Article

References (27)

1. Ansfield FJ (1975) A randomized phase III study of four dosage regimens of 5-fluorouracil. Proc Am Assoc Cancer Res 16: 224 (abstract)
2. Blum J, Jones S, Buzdar A (2001) Capecitabine (Xeloda) in 162 patients with paclitaxel-pretreated MBC: updated results and analyses of dose modification (abstract 693). Eur J Cancer 37(Suppl 6): S190 (abstract)
3. Cascinu S, Del Ferro E, Catalano G (1996) Toxicity and therapeutic response to chemotherapy in patients aged 70 years or older with advanced cancer. Am J Clin Oncol 19: 371-374
4. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schilsky RL (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with iv 5-fluorouracil/leucovorin. Ann Oncol 13: 566-575
5. Chiara S, Nobile MT, Vincenti M, Lionetto R, Gozza A, Barzacchi MC, Sanguineti O, Repetto L, Rosso R (1998) Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol 42: 336-340
6. Dahl O, Horn A, Mella O (1994) Do acute side-effects during radiotherapy predict tumor response in rectal carcinoma? Acta Oncol 33: 409-413
7. Diasio RB, Beavers TL, Carpenter JT (1988) Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil- induced toxicity. J Clin Invest 81: 47-51
8. Diasio RB (1998) The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. Oncology (Huntingt) 12: 23-27
9. Grothey A, Sargent D, Goldberg R, Schmoll HJ (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil, leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22: 1209-1214
10. Johnson MR, Hageboutros A, Wang L, High L, Smith JB, Diasio RB (1999) Life-threating toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 5: 2006-2011
11. Köhne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schoffski P, Micheel S, Hecker H (2002) Clinical determinants of survival in patients with 5-fluorouracil based treatment for metastatic colorectal cancer: results of a multivariate analyses of 3825 patients. Ann Oncol 13: 308-317
12. Kuilenburg AB, Muller EW, Haasjes J, Meinsma R, Zoetekouw L, Waterham HR (2001) Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14 + IG > A mutation causing DPD deficiency. Clin Cancer Res 7: 1149-1153
13. Landis SH, Murray T, Bolden S (1999) Cancer statistics 1999. CA Cancer J Clin 49: 8-13
14. Midgley R, Kerr D (1999) Colorectal cancer. Lancet 353: 391-399
15. Milano G, Etienne M, Pierrefite V, Barberi-Heyob M, Deporte-Fety R, Renee N (1999) Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 79: 627-630
16. Moertel CG, Reiemeier RJ (1969) Advanced Gastrointestinal Cancer. Clinical Management and Chemotherapy. New York: Harper & Row Pubs Inc.
17. Popescu RA, Norman A, Ross PJ, Parikh B, Cunninham D (1999) Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 17: 2412-2418
18. Rothenberg ML, Meropol NJ, Poplin EA, van Cutsem E, Wadler S (2001) Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19: 3801-3807
19. Scheithauer W, Kornek GV, Raderer M, Schuell B, Schmid K, Kovats E, Schneeweiss B, Lang F, Lenauer A, Depisch D (2003) Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 21: 1307-1312
20. Scheithauer W, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Gedlicka C, Schull B, Brugger S, Schneeweiss B, Lang F, Lenauer A, Depisch D (2001a) Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer. J Clin Oncol 20: 165-172
21. Scheithauer W, Kornek GV, Schuell B, Ulrich-Pur H, Penz M, Raderer M, Lang F, Schneeweiss B, Lenauer A, Depisch D (2001b) Second-line treatment with oxaliplatin+raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy. Ann Oncol 12: 709-714
22. Scheithauer W, Kornek GV, Ulrich-Pur H, Penz M, Raderer M, Salek T, Haider K, Kwasny W, Depisch D (2001c) Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma. Cancer 91: 1264-1271
23. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D (1993) Randomized comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 306: 752-756
24. Sloan JA, Goldberg RM, Sargent DJ, Vargas-Chanes D, Nair S, Cha SS, Novotny PJ, Poon MA, O'Connell MJ, Loprinzi CL (2002) Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 20: 1491-1498
25. Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropoe NJ (1995) Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 74: 11-17
26. Van Rijnsoever M, Grieu F, Elsaleh H, Joseph D, Iacopetta B (2002) Characterization of colorectal cancers showing hypermethylation at multiple CpG islands. Gut 51: 797-802
27. Williams NS, Northover JMA, Arnott SJ (1995) Colorectal tumors. In Oxford Textbook of Oncology, In Peckham M, Pinedo H, Veronesi U (eds) Oxford, UK: Oxford University Press, pp 1133-1168